Pleased to share my job talk paper "Breakthrough or Breakaway Innovation?" is now out. It argues expedited regulatory review and liability immunity are a bad combination of policy tools, using the US FDA's Breakthrough Devices Program as a case study.
journals.library.columbia.edu/index.php/st...